Pressure Biosciences Inc (PBIO)

[velcro]

Worth noting, one month ago, the Directors received "free" shares which they are holding long.

[Singhania]

Stocks in the News: $PBIO, $THRM.V / $TBRIF, $ALST, $ZRFY, $SNRG https://thestreetreports.com/stocks-in-the-news-pbio-thrm-v-tbrif-alst-zrfy-snrg/

[velcro]

This very well could be a success and a profit.

[blue_skies]

this is a $5 stock

[Singhania]

#BreakingNews $PBIO Pressure BioSciences Forges Game Change #Technology in Canada’s Cannabis Industry

SOUTH EASTON, MA - January 19, 2023 - Pressure BioSciences, Inc. (OTCQB: PBIO) today announced results from initial consumer focus group testing of a THC Nanoemulsion Oral Spray prepared using PBI's revolutionary Ultra Shear Technology™ (UltraShear™ or UST™) platform. Preparation of the THC Nanoemulsion Oral Spray was completed and Delivers First Effects and Maximization in Lightning Speed Just Simple, Reliable Dosing Delivers Profoundly Improved Results Read more
https://finance.yahoo.com/news/pressure-biosciences-nanoemulsions-platform-forging-123000350.html

[AveragePenny]

$PBIO Pressure BioSciences Nanoemulsions Platform Forging Game-Changing Future for Cannabis Industry

https://www.accesswire.com/735883/pressure-biosciences-nanoemulsions-platform-forging-game-changing-future-for-cannabis-industry

Dramatic Consumer Testing Results Confirm UltraShear Nanoemulsion THC Oral Spray Delivers First Effects and Maximization in Lightning Speed - Simple, Reliable Dosing Delivers Profoundly Improved Results

SOUTH EASTON, MA / ACCESSWIRE / January 19, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or "Company") today announced results from initial consumer focus group testing of a THC Nanoemulsion Oral Spray prepared using PBI's revolutionary Ultra Shear Technology™ (UltraShear™ or UST™) platform. Preparation of the THC Nanoemulsion Oral Spray was completed by PBI's California-based partner companies, including Crème De Canna (CdC), a CA-licensed manufacturer and long-established provider of innovative, high-quality cannabis products in CA.

Mr. John B. Hollister, PBI's Director of Sales and Marketing, explained: "Cannabinoids like THC are oil-soluble molecules that are typically poorly absorbed when ingested by our water-based human bodies. For THC edibles, most consumers report waiting 30-60 minutes for first effects and 60-90 minutes to peak effects. Impatient consumers may repeatedly consume their edibles, only to be unhappily over-dosed two hours later. Conversely, smoking and vaping produce first effects immediately and peak effects quickly but are increasingly in disfavor for the well-known respiratory health consequences that accumulate."

Mr. Hollister continued: "PBI's partners in California used our revolutionary UltraShear platform to prepare extreme nanoemulsions of THC into an Oral Spray for consumer testing. Multiple test groups have confirmed that the UltraShear Nanoemulsion THC Oral Spray produces first effects between 1-10 minutes, often in the first 1-5 minutes, with peak effects reached in 15-60 minutes, often within 15-30 minutes. This testing has provided dramatic consumer-level validation in the cannabis market for our UltraShear nanoemulsion capabilities and for its expected market-changing impact. We are anticipating substantial revenues from the first THC UltraShear Nanoemulsion Oral Spray to be marketed by our California partners, beginning in this quarter."

Mr. Jonathan Kolodinski, President of CdC, said: Crème De Canna is very excited to partner with PBI on the development of this groundbreaking dosing modality that will disrupt the global cannabis marketplace. This innovative product has strongly addressed the needs and concerns from both the edibles and inhalation sides of the cannabis consumer marketplace. It provides an easy to use, reliable, and healthy alternative dosing format, with the immediate onset and consistent experience associated with inhalables but without the respiratory health risks, and it eliminates the frustrating delayed effects, imprecision, and frequent overdosing associated with edibles, as well as the calories!"

Mr. Kolodinski further stated: "Utilizing PBI's UST platform, we successfully formulated cannabinoids into a clear, effectively water-soluble, extremely fine nanoemulsion that is conveniently and effectively delivered via an oral mist, providing the consumer with near-immediate onset and rapid peak effects. The consumer testing results announced today herald the dramatic reshaping we expect will follow in the cannabis markets. We are excited to continue to research the impacts of various combinations of cannabinoids, terpenoids, and other compounds to produce highly functional cannaceutical products to improve the lives of people around the world."

Mr. Jeffrey N. Peterson, Chairman of PBI, summarized: "It was extremely satisfying to see our consumer study objectives in assessing THC UltraShear Nanoemulsions for absorption speed and potency, easy and precise dosing, and avoidance of the slow and unreliable under/over-dosing of edibles so well demonstrated. Nonetheless, this was fully anticipated based upon the UltraShear platform's astonishing demonstrated successes to date across applications spanning industries from pharmaceuticals and nutraceuticals to cosmeceuticals, food and beverages, agrochemicals, and more. PBI's UltraShear platform offers a game-changing redefinition of the terms of competition for our partners addressing these diverse multi-billion-dollar market opportunities, and we are very excited about the path ahead for PBI and our partners in 2023 and beyond."

[AveragePenny]

$PBIO Pressure BioSciences Gives Guidance for Strong Q4 2022 Sales Followed by Rapid Revenue Growth from Multiple Large Industries in 2023

https://www.accesswire.com/733032/pressure-biosciences-gives-guidance-for-strong-q4-2022-sales-followed-by-rapid-revenue-growth-from-multiple-large-industries-in-2023

SOUTH EASTON, MA / ACCESSWIRE / December 22, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty process development and production services to the worldwide nutraceuticals, cosmetics, biotherapeutics, and food/beverage industries, among others, today offered guidance that the Company believes its Q4 2022 revenue will exceed quarterly revenue for any quarter over the past four years, and may achieve the highest quarterly revenue ever for the Company. PBI believes the foundations built and momentum achieved over the past several months will continue to accelerate, driven primarily by the recent commercial release of its revolutionary Ultra Shear Technology™ (UltraShear™ or UST™) platform. The Company further believes Q1 2023 revenue will greatly exceed Q4 2022's expected strong results, and that revenues in each successive quarter will surpass the prior quarter's level. Management expects the Company to reach breakeven/profitability by the end of 2023.

Future Outlook (The Stage Has Been Set): Q4 2022 & FY 2023.

Revenue
Q4 2022: PBI expects to report highest quarterly revenue in past 4 years, likely highest ever.
FY 2023: each quarter expected to exceed prior quarter's revenue. UltraShear revenues expected to top $10M for 2023, beginning with over $1M in Q1 2023.
Agreements (UltraShear Toll Processing)
Company ending 2022 with 4 executed agreements; very close to final execution of six or more agreements.
Each agreement estimated to yield $1M or more in incremental annual revenue.
CBD
Expect data releases in Q1 2023 from key opinion leaders in academia and patient treatment/advocacy, supporting PBI's UltraShear Nano-CBD as among Best-in-Class in Bioavailability globally.
THC
MA and CA market focus group studies underway to demonstrate expected superior speed of onset and absorption, supporting PBI's UltraShear Nano-THC as among Best-in-Class in Bioavailability globally.
Nutraceutical Supplements
Supply agreement with several multi-billion-dollar nutraceutical supplement leaders to be closed by mid-2023; strategic investment expected.
Immune Booster
Discussions underway with quality-leading, top-selling suppliers seeking assistance to nanosize oil-based active ingredients to be included in new, powerful Immune Booster product…including PBI's proven capabilities in curcumin, astaxanthin, and CBD.
Cosmetics:
PBI anticipates the Dr. Denese SkinScience partnership will strongly leverage data generated in 2022 studies of PBI's UltraShear processed Retinol and Lipid-Soluble Vitamin C, and from current on-going studies, to powerfully validate capabilities of UltraShear-enabled, next-generation, anti-aging serums from Dr. Denese, and will drive new achievements from her existing QVC marketing engine (with over $500M sales over 20 years), starting in Q1 2023.
How the Stage was Set: Review of FY 2022 Key Accomplishments

April: critical pivot in business focus from PCT Platform to Ultra Shear Technology Platform.
April: early access program for UltraShear nanoemulsion processing platform announced.
May: first agreement to make UltraShear-based Nano-CBD product - expected 2023 product revenues of $1M.
June: PBI partner Ohio State publishes/presents data to support UltraShear role in global $41B plant protein market.
July: second $1M+ agreement to process commercial UltraShear-based Nano-CBD products announced.
August: third agreement to process commercial Nano-CBD products. Projected FY 2023 revenues to exceed $3M.
August: PBI secures pivotal partnership with Dr. Denese SkinScience - QVC leader with $500M 20-year sales.
October: PBI and Dr. Denese announce UltraShear-enabled anti-aging and hair regrowth products for 2023 release.
December: Dr. Denese reports data on UltraShear Nano-Retinol greatly exceeds all performance expectations.
December: first commercial production of revolutionary UltraShear processed Nano-CBD product shipped and paid.
Mr. Richard T. Schumacher, President and CEO of PBI, commented: "Our development of UltraShear over the past 6 years presented a pivotal, game-changing nanoemulsions technology that we believe will restate the basis of competition for a myriad of products across multiple major industries. We have assembled a strong and differentiated IP position and unique engineering and scientific expertise to unleash this opportunity, for PBI and for clients worldwide. We made the critical decision in early 2022 to pivot our business focus and resources almost entirely onto accelerating the UltraShear platform, building commercial-stage UST processing equipment, creating pivotal technology demonstrations with select partners in multiple industries, and accelerating our path to commercial traction and a revenue growth inflection."

Mr. Schumacher concluded: "Our team has navigated a very challenging path to the achievement of this pivot point, and we are proud of what we have built. The stage has been set. Initial partners have been secured and our first commercial UltraShear product has been delivered and paid. Astonishing early demonstrations of UltraShear's unique differentiation of products continue to mount up, and more partners and early marketing results are gathering already for revenue acceleration in Q1 and throughout all of 2023. We are grateful daily for the patient support of our many long-term investors, and we are excited to have them at our side as PBI enters an exciting new era of revenue growth, profitability, and a planned uplist to a national exchange in 2023."

[AveragePenny]

$PBIO Pressure BioSciences Announces First Commercial Production of Revolutionary UltraShear Nanoemulsion Product Shipped, Booked, and Paid

https://www.accesswire.com/731628/

$75,000 Pilot Lot Payment Received for Phase I of Safer Medical of Montana Agreement; Phases II/III Commercial Scale-Up Scheduled for Early 2023 - Expected to Yield 1st Half 2023 Revenues Over $1 Million

SOUTH EASTON, MA / ACCESSWIRE / December 13, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty process development and production services to the worldwide nutraceuticals, cosmetics, biotherapeutics, and food/beverage industries, among others, today confirmed the shipment of the Company's first ever commercial production lot of a revolutionary nanoemulsion product created and enabled by the Company's innovative Ultra Shear Technology™ (UST™ or UltraShear™) nanoemulsification platform. The shipped product is a breakthrough CBD oral spray designed by PBI for fast effect and high potency for Safer Medical of Montana ("SMM"), with whom PBI signed a multi-year development and manufacturing agreement ("Agreement"), announced on May 4, 2022. SMM pre-paid the entire $75,000 purchase price of the Phase I production lot.

The Agreement covers three phases of development and commercialization of a custom-formulated oral spray of hemp-derived nanoemulsified CBD designed for extremely rapid absorption and effectiveness, and for efficient high potency delivery of CBD active material in each dose. All ingredients used in the manufacture of this UltraShear prepared nanoemulsion product are sourced from naturally-occurring, plant-based origins. Phases II and III of the PBI-SMM Agreement are focused on scaling up UltraShear nanoemulsion production by a factor of 10x in each stage, with total PBI revenues captured under this Agreement expected to top $1M in Q1/Q2 of 2023.

Captain George Ackerson, the CEO and Founder of Safer Medical of Montana, stated: "I am so excited by our opportunity to partner with Pressure BioSciences in allowing the launch of their first UltraShear-enabled nanoemulsion product to be focused upon creation of our revolutionary "Black Ops Nano CBD" oral spray, which is specifically targeted to serving vast unmet needs within the U.S. veterans community. Their UltraShear technology platform allows an oil-soluble active molecule like CBD to be prepared into a nanoemulsion of vanishingly tiny oil droplets in water that ensures rapid absorption and unparalleled bioavailability of the CBD into the water-based biochemistry of human bodies. Development work to date has demonstrated these capabilities far beyond any CBD products currently on the market - with performance better than we could have dreamed."

Captain Ackerson continued: "As a Vietnam veteran myself, I wanted to make certain that our CBD product had the best chance of helping the men and women who have served our Country, many of whom still struggle daily with significant health and wellness issues. To ensure optimal effectiveness with fast validation in a positive first use experience, we requested the development of a very high concentration of CBD (40mg per milliliter), which is beyond the concentration capabilities of currently marketed true nano formulations. Each bottle contains 2000mg of CBD. One spray will deliver about 6.5mg of the nanoemulsified CBD, designed for fast absorption through the cheek or under the tongue. Individual users will be able to adjust their dosage easily and rapidly as needed."

Mr. John B. Hollister, Director of Sales and Marketing at PBI, observed: "This launches a new chapter for Pressure BioSciences, as UltraShear commercialization enters into a phase of scale up and rapid growth. PBI has long established itself as an expert in the development and application of extreme high-pressure technology to enable remarkable and important new scientific and production capabilities, but UltraShear now opens an extraordinarily broad range of important and large new commercial application markets, from pharmaceuticals to nutraceuticals, cosmetics, food and beverages, agrochemicals, and many more."

Mr. Hollister continued: "Black Ops Nano CBD is the first UltraShear product, but vastly more products, far beyond this initial cannabinoid opportunity, will quickly follow. We have previously announced exciting progress in our cosmeceutical partnership with Dr. Denese SkinScience, and in our formulation developments for astaxanthin (the most potent antioxidant in the market) and other nutraceuticals. Our investors should expect to hear much more about additional UltraShear contracts and products in the days and weeks ahead. The dam is bursting."

Mr. Richard T. Schumacher, President and CEO of PBI, concluded: We recently announced the first three cosmeceutical products targeted for development and commercialization with Dr. Adrienne Denese through the initial quarters of 2023 PBIO/Dr. Denese FORCE Webinar 101322. Combined with the CBD product formulations already announced with orders from Captain Ackerman and other partners, we expect these UltraShear products to yield at least $4 million of incremental new toll manufacturing revenues for PBI through Q1/Q2 of 2023. We are also close to executing a number of additional UltraShear contracts that we anticipate will drive Q3/Q4 2023 tolling revenues well beyond the expected Q1/Q2 record revenues created by the UltraShear platform. This is a wonderful time to consider becoming or being a stakeholder in Pressure BioSciences."

[AveragePenny]

$PBIO Pressure BioSciences, Inc. Reports Q3 2022 Financial Results and Offers Business Update on Ultra Shear Technology Nanoemulsions Commercialization Progress

https://www.accesswire.com/727750/pressure-biosciences-inc-reports-q3-2022-financial-results-and-offers-business-update-on-ultra-shear-technology-nanoemulsions-commercialization-progress

Resources Continue to Pivot to UST Platform Commercialization, Achieving Major Progress and Traction; Revolutionary Nanoemulsions Technology Expected to Drive Major Growth to Profitability in 2023

Investor Call Scheduled for Tuesday, November 22, 2022 at 4:30 p.m. ET

SOUTH EASTON, MA / ACCESSWIRE / November 22, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty process development and production services to the worldwide biotechnology, biotherapeutics, nutraceuticals, cosmetics, agrochem, and food & beverage industries, today reported financial results for the third quarter ended September 30, 2022, provided a business update, and offered guidance for a strong finish to 2022 and growth drive to expected profitability in 2023.

Financial Results: Q3 2022 vs. Q3 2021

Total revenue for Q3 2022 was $144,000 compared to $518,000 for the Q3 2021, a decrease of 72%.
Instrument sales for Q3 2022 were $134,000 compared to $419,000 for Q3 2021, a decrease of 66%.
PBI Agrochem subsidiary sales in Q3 2022 were $10,000 compared to $17,000 for Q3 2021, a decrease of 41%.
Operating loss for Q3 2022 was $1,363,000 compared to $1,243,000 for Q3 2021, an increase of 10%.
Basic and diluted net loss per share was $(0.44) for Q3 2022, improved from $(0.82) for Q3 2021.
Director of Sales and Marketing for PBI, Mr. John B. Hollister, commented: "While overall sales and new business development trending for PBI remains extremely positive, our Q3 2022 revenue results were disappointing and well below initial expectations but are rebounding as expected in Q4 2022. This decrease was primarily due to two key factors: (i) the timing of product purchase orders, as several large orders expected in the third quarter were not received until the fourth quarter, and (ii) our strategic pivot in the Company's focus and resource allocations away from PCT & BaroFold product and services areas and almost entirely onto the launch and rapid sales growth expected from Ultra Shear Technology™ (UST™) Tolling Services. We are already seeing the significant recovery expected in revenues during Q4 2022."

Mr. Hollister continued: "With our organization now fully focused on the commercialization of the UST platform since early 2022, we are extremely optimistic about our planned acceleration in revenues, beginning in Q4 2022. Our team has attended several industry meetings over the past three months that focused on products and sales channels with high potential for game-changing impact from our novel UST nanoemulsions platform. The interest in this revolutionary technology from many different application and product areas has been compelling, even breathtaking. Our priority now is on manufacturing additional UST equipment and gearing up our UST tolling services as rapidly as possible. Our goal is to capitalize on the burgeoning demand to close additional committed UST contract production capacity and drive our 2023 revenue growth."

Recent Operational and Technical Highlights:

October 26: PBI and skincare pioneer and leading innovator Dr. Adrienne Denese, M.D., Ph.D. to introduce revolutionary UST nanoemulsion-based hair loss prevention and hair regrowth product line in 2023.
September 28: Imminent Commercial Launch of Revolutionary UST Processing Method to be Focus of PBI's Presentation at Emerging Growth Conference 40.
September 27: Unique Advantages and Commercial Process Scalability of PBI's Revolutionary UST Platform Illuminated at the Conference of Food Engineering 2022.
September 13: Pressure BioSciences to Expand on Pivotal Change in Business Strategy with Presentation at HC Wainwright Annual Global Investment Conference.
August 24: PBI secures pivotal cosmeceuticals partnership for UST platform with Dr. Denese SkinScience, a 20-year industry leader with over $500 million in QVC sales.
August 18: Third contract announced for hemp-derived CBD products, estimating $2 million 2023 revenue.
August 11: PBI receives approval to manufacture hemp-derived CBD products in Mass, including novel CBD nano emulsions processed by the Company's revolutionary Ultra Shear Technology (UST) platform.
Mr. Richard T. Schumacher, President and CEO of PBI, added: "We made the decision in early 2022 to reallocate staff and resources off of our PCT and BaroFold platforms and to focus them almost exclusively on UST commercialization. We anticipated that PCT/BaroFold revenues could be adversely affected through this transition, which we unfortunately observed in the third quarter of 2022. However, the fourth quarter is shaping up to be very robust, even before the addition of new UST tolling revenues significantly enter our revenue mix. Sales of booked/shipped products through mid-November have already exceeded total sales of Q2 2022 by 2x, and we are on target to report all-time quarterly record revenue in Q4 2022. This strong revenue growth is expected to include approximately $100,000 in initial UST commercial sales and over $70,000 of PBI Agrochem sales, both of which we believe to be important harbingers of strong revenue in 2023."

Mr. Schumacher continued: "We manufactured the initial lot of our Nano-CBD Spray product this month and will be shipping it to our customer (Safer Medical of Montana) shortly, following quality control release. Our attendance at last week's MJ Biz Conference as well as two recent cannabis beverage meetings has generated so many immediate partnering and client opportunities that it is demanding careful prioritization of our resources, as we focus on funding for growth acceleration through 2023. We believe our achievements in Q4 2022 and FY 2023 will be many, including: (i) substantial and accelerating revenues from initial sales of our Ultra Shear toll processing activities in cannabis applications, other major nutraceuticals, and in skincare; (ii) successful opening of the PBI - OSU (The Ohio State University) Food Safety Consortium, introducing the UST platform across the food and beverages industry, planned for December 8, 2022 at OSU; (iii) major nutraceuticals partnership with a leading global multi-national, multi-billion-dollar corporation; (iv) up-listing of PBIO to a national stock exchange; and (v) profitability by or before the end of 2023."

Mr. Jeffrey N. Peterson, PBI's Chairman, concluded: "We greatly appreciate the steadfast base of long-term investors who have delivered PBI to this pivotal moment in our trajectory. Our team and our partners are highly motivated by PBI's recent successes and strengthening in our patented UST platform. We believe that 2023 will deliver a hockey stick inflection moment as "the new PBI" charts its new course, while redefining the terms of competition with UST nanoemulsified products in multiple, diverse, and multi-billion-dollar markets."

[AveragePenny]

$PBIO Pressure BioSciences, Inc. to Discuss Third Quarter 2022 Financial Results and Provide Business Update

https://www.accesswire.com/727546/pressure-biosciences-inc-to-discuss-third-quarter-2022-financial-results-and-provide-business-update

Conference Call Scheduled for Tuesday November 22 at 4:30pm ET

SOUTH EASTON, MA / ACCESSWIRE / November 21, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" and the "Company") today announced that the Company will host a teleconference to discuss its Third Quarter 2022 financial results and to provide a business update. Anyone interested may listen to the teleconference either live (by telephone) or through a replay (by telephone or via a link on the Company's website) approximately one day after the teleconference.

The teleconference will include a Company presentation followed by a Question & Answer period.

Date: Tuesday, November 22, 2022. Time: 4:30 PM Eastern Time (ET).

To attend this teleconference, live by telephone: Dial-in: [phone] (North America); [phone] (International). Verbal Access Code: 521494 (or say Pressure BioSciences Q3 Conference Call)

For those unable to participate in the live teleconference, a replay will be available beginning Wednesday, November 23, 2022. The replay will be accessible via telephone and the Company's website for 30 days.

Replay Number: [phone] (North America); [phone] (Int'l); Replay Passcode: 47167.

[AveragePenny]

$PBIO Pressure BioSciences and Leading Cosmeceuticals Innovator Dr. Denese SkinScience to Introduce Revolutionary UST Nanoemulsion Hair Regrowth Product in 2023

https://www.accesswire.com/722383/pressure-biosciences-and-leading-cosmeceuticals-innovator-dr-denese-skinscience-to-introduce-revolutionary-ust-nanoemulsion-hair-regrowth-product-in-2023

Dormant Hair Follicles to be More Effectively Revitalized by Nutrients and Therapeutics Delivered Quickly and Potently via Extremely Fine Droplet Sizes Produced from Patented UST Nanoemulsion Technology

SOUTH EASTON, MA / ACCESSWIRE / October 26, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty testing services to the worldwide cosmetics, nutraceuticals, biotherapeutics, and food/beverage industries, among others, today confirmed specific product rollout plans agreed in their wide-ranging partnership with science-driven skincare industry leader Dr. Denese SkinScience, which were shared recently in the FORCE Family Office sponsored Development of a New Generation of Skincare Products webinar (PBIO/Dr. Denese FORCE Webinar 101322). Highlighting Dr. Denese's world renown expertise and long-established leadership role as an innovator in skincare, the webinar revealed that the two companies had chosen three additives/areas for their initial collaborative development of valuable new skincare product lines, all of which would leverage PBI's proprietary UST nanoemulsification process: (i) retinol, (ii) lipid-soluble Vitamin C, and (iii) hair loss prevention/hair regrowth.

Dr. Adrienne Denese, M.D., Ph.D. a globally-acknowledged skincare visionary, anti-aging pioneer, and President of Dr. Denese SkinScience, explained: "The pivotal challenge in cosmeceuticals and skincare products is to deliver our scientifically designed payloads of critical nutrient and therapeutic ingredients in a speedy, complete, and precise fashion while penetrating through the difficult resistive barrier of skin down to the living dermal tissues beneath it. So many of these key ingredients are "oily" or lipophilic molecules that do not normally mix well with water, making them difficult to effectively deliver for absorption by the water-based biochemistry of human bodies. The revolutionary breakthrough of PBI's industrially-scalable UST platform technology for making nanoemulsions of extremely-fine nano-droplet sizes, that are subsequently stable and can deliver nutrients and therapeutic payloads with unprecedented effectiveness, is undoubtedly one of the most important scientific and process breakthroughs for our industry in my lifetime."

Dr. Denese continued: "From my patients and customers, the single most-requested addition to our product line is an effective intervention for hair loss and hair regeneration - and it is considered vastly more urgent in age-related hair loss for women, beyond the enormous demand amongst men. We believe that the challenge of truly effective delivery of stimulation and revitalization to weakening and dormant hair follicles will finally be overcome with the entry of PBI's UST nanoemulsions platform technology, and we are now planning to deliver an effective solution to that challenge. In just a few weeks since making this decision, my team and I have made tremendous progress on the development of our first-ever hair loss prevention/hair restoration product line. With progress to date, we are now targeting to launch the first products in this new, exciting product line in time for the Christmas 2023 buying season. What a gift that would be for our existing and loyal base of over 500,000 QVC customers and for many more eager new buyers!"

Gary Smejkal, Senior Scientist at PBI, said: "We have also made wonderful progress lately in the development of UST-processed retinol and lipid-soluble Vitamin C. These very high quality nanoemulsions consist of oil droplets that are consistent and extremely small. At about 50 nanometers they are far smaller than the wavelength of visible light, which makes them highly transparent; they are also expected to be stable and effectively water soluble. These initial nutrients and therapeutic nanoemulsion ingredients should be available to Dr. Denese SkinScience for inclusion in their skincare products by the middle of 2023."

Richard T. Schumacher, President and CEO of PBI, summed up the progress: "We believe that PBI's UST nanoemulsified retinol and lipid-soluble Vitamin C enhanced products will add valuable new dimensions to multiple Dr. Denese SkinScience products starting in mid-2023. Most excitingly, it appears now that the new hair loss prevention/hair restoration product line should be ready for marketing in about one year, which means these products could add millions in revenue to PBI's 2023 results. This would be additive to the approximately five million dollars in revenue we believe will be received in 2023 from completion of the three new nano-CBD contracts that have announced over the past several months and that we expect to complete in 2023, with shipments beginning in next year's first quarter."

Mr. Schumacher concluded: "Dr. Adrienne Denese is a titan in the cosmeceuticals/skincare industry worldwide and has accumulated sales over $500 million through QVC alone! Her life mission has been to help women look and feel younger and to live healthier lives. She has relentlessly focused on science, quality, potency, and effectiveness in her products over all else. We feel immensely privileged to have won her support and close partnership between our companies. These are indeed very exciting times for all stakeholders in PBIO."

[AveragePenny]

$PBIO Pressure BioSciences and Leading Cosmeceuticals Company Dr. Denese SkinScience Present Their Partnership Progress in FORCE Family Office October 13th Webinar

https://www.accesswire.com/719859/pressure-biosciences-and-leading-cosmeceuticals-company-dr-denese-skinscience-present-their-partnership-progress-in-force-family-office-october-13th-webinar

Companies Will Discuss Actions and Planning Completed for a New Generation of Skincare Products, Offering Revolutionary Effectiveness Through Combination of PBI's UST Best-in-Class Nanoemulsification Technology with Dr. Denese's Unparalleled Science-Driven Understanding of the Needs in the Skincare Market

SOUTH EASTON, MA / ACCESSWIRE / October 11, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" and the "Company"), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments, consumables, and specialty testing services to the worldwide cosmeceuticals, health and wellness, and other industries today announced the Company's participation in the October 13th Development of a New Generation of Skincare Products webinar, sponsored by FORCE Family Office. PBI is honored to be joined by QVC icon, skincare visionary, and anti-aging pioneer Adrienne Denese, M.D., Ph.D. Dr. Denese is the President of Dr. Denese SkinScience, one of the most successful skincare lines in the U.S., with accumulated sales over $500 million through QVC.

PBI's revolutionary Ultra Shear Technology™ (UST™) platform, and its' critical enabling role in the development of a new generation of skincare products, will be the focus of this real-time, interactive "Presentation/Q&A Event". UST is a revolutionary and industrially-scalable technology that can process oil and water mixtures into nanoemulsions, in which large oil drops in water (containing active ingredients) are reduced to nano-sized oil droplets so small they achieve effective water-solubility and long-term stability. These high quality nanoemulsions show significantly increased absorption and bioavailability of the therapeutic active ingredients contained in the nano-sized oil droplets. Examples of active ingredients include retinol, vitamins, supplements, and nutraceuticals - all of which are routinely infused into cosmeceuticals.

Dr. Adrienne Denese's life mission has been to help women look and feel younger, and to live healthier lives. Her immutable priority has always been to effectively develop and deliver the highest quality active ingredients to her customers. Dr. Denese explained: "I am excited to partner with PBI as we together use the UST platform's remarkable breakthrough in nanoemulsion effectiveness to develop a new generation of category-changing skincare products that will offer more effective absorption, bioavailability, and therapeutic benefits to Dr. Denese SkinScience customers worldwide."

DATE: Thursday, October 13, 2022 (Noon ET)
PRESENTATION: Video Webcast
REGISTER: Click here to register for the Webinar

Panelists

Pressure BioSciences, Inc. (OTCQB:PBIO) announced on Wednesday, September 28th the imminent commercial launch of its revolutionary UST nanoemulsification processing method, with an initial focus in the CBD market. Company expects Q4 2022 incremental revenue to be in the hundreds of thousands of dollars and in the millions of dollars for FY 2023. Mr. Richard T. Schumacher, Founder and CEO, will be a panel participant.
Dr. Denese SkinScience is one of the most successful, highly-rated, award-winning, and longest-lasting skincare lines in the history of QVC. Dr. Adrienne Denese, Founder and President, will be a panel participant.
FORCE Family Office is the largest network of family offices in the United States. FORCE is dedicated to helping family offices efficiently and successfully connect with private and public companies for co-investment, research, education, and philanthropy. CEO Steven Saltzstein will be the Moderator of the webinar.
Selected Recent Key Announcements - PBIO

Pressure BioSciences Secures Pivotal Cosmeceuticals Partnership for UST Platform with Dr. Denese SkinScience, 20-Year Industry Leader with Over $0.5 Billion in QVC Sales.
Pressure BioSciences Announces First Nanoemulsions Manufacturing Agreement Under Recently Released UST Early Access Program

[AveragePenny]

$PBIO Imminent Commercial Launch of Revolutionary UST Processing Method to be Focus of Pressure BioSciences Presentation at Emerging Growth Conference 40 on September 28, 2022

https://www.accesswire.com/717781/imminent-commercial-launch-of-revolutionary-ust-processing-method-to-be-focus-of-pressure-biosciences-presentation-at-emerging-growth-conference-40-on-september-28-2022

Multiple Shipments of Hemp-Derived Nanoemulsified CBD Planned for Q4 2022 to Fill Existing Orders for Bulk Material Destined for White Label Use; Company Expects Q4 2022 Incremental Revenue in the Hundreds of Thousands of Dollars and in the Millions of Dollars for FY 2023

SOUTH EASTON, MA / ACCESSWIRE / September 28, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" and the "Company"), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments, consumables, and specialty testing services to the worldwide food and beverage, health and wellness, nutraceuticals, cosmetics, pharmaceuticals, and other key industries, today announced the Company's participation in the September 28th Emerging Growth Investor Conference. This real-time, interactive conference will feature a number of exciting, rapidly-growing publicly traded companies, presenting for 30-45 minutes each. PBI's President and CEO, Mr. Richard T. Schumacher, is scheduled to be the first presenter of the conference, speaking at 9:00 am ET. Mr. Schumacher will focus the majority of his talk on the much-anticipated commercial launch of the Company's powerful, patented, and unique Ultra Shear Technology™ (UST™) nanoemulsification platform.

Over the past few months, PBI has announced the execution of three agreements covering the production, distribution, commercial roll-out, and financial partnership for novel, effectively water-soluble, highly bioavailable, nanoemulsified CBD products for both oral and topical use. Recently, the Company also announced the execution of a cosmeceuticals partnership with Dr. Denese SkinScience, a 20-year skincare industry leader with over $500 million in QVC sales.

All four contracts are based on the use of the UST platform to develop nanoemulsions of oil-based nutraceuticals and cosmetics. Nanoemulsions are known to turn oil-based active ingredient mixtures (e.g., CBD, THC, Astaxanthin, Curcumin, Retinol, Prednisone) into long-term stable, effectively water-soluble, highly bioavailable formulations. The Company believes these four contracts alone could generate over $5 million of accretive revenue for PBI in 2023. The Company plans to close on a minimum of six additional contracts over the remaining months of FY 2022, further adding to 2023 revenue.

DATE: Wednesday, September 28, 2022 (9:00 am ET)
PRESENTATION: Video Webcast - Presentation plus Q&A
REGISTER: Click here to register for the Conference

Highlights of PBI's Recent Press Releases on the Imminent Launch of UST-Processed, Nanoemulsified CBD and Cosmeceutical Products - with Estimated Annual 2023 Revenue to PBI Expected to Exceed $5,000,000:

PBI has executed three contracts that call for the Company to manufacture thousands of liters of UST-processed CBD nanoemulsion bulk material during Q4 2022
CBD bulk nanoemulsion material will be sent to the Company's distributors who will vial, label, and sell the material via their e-commerce sites, sub-distributors, and other established sales channels
These unique products are expected to be long-term stable, effectively water-soluble, highly bioavailable nanoemulsions of CBD for oral and topical use
Formulation of the initial products has been completed: only plant-based reagents are used in the products
These companies have distribution channels and infrastructure for their current health & wellness products
PBI believes Q4 2022 UST-processed nano-CBD Pilot manufacturing revenue will meet or exceed $250,000
PBI believes first-year (FY 2023) UST-processed nano-material revenue will meet or exceed $5M
PBI believes no other CBD product on the market can compete with the quality of its UST-processed Nano-CBD
PBI has also announced a partnership with Dr. Denese SkinScience to manufacture new and to enhance existing skincare products sold under the Dr. Denese label. UST-processed products are expected for FY 2023 release.

[AveragePenny]

$PBIO Presenting on the Emerging Growth Conference on September 28 Register Now

https://www.globenewswire.com/news-release/2022/09/27/2523160/0/en/Presenting-on-the-Emerging-Growth-Conference-on-September-28-Register-Now.html

9:00 – 9:30
Pressure Biosciences, Inc. (OTCQB: PBIO)
Keynote speaker: Richard T. Schumacher, President / CEO

[AveragePenny]

$PBIO Pressure BioSciences to Expand on Pivotal Change in Business Strategy with Presentation at H. C. Wainwright Annual Global Investment Conference on September 13th

https://www.accesswire.com/715767/pressure-biosciences-to-expand-on-pivotal-change-in-business-strategy-with-presentation-at-h-c-wainwright-annual-global-investment-conference-on-september-13th

Company Shifts Primary Business Focus to Revolutionary UST Platform. Expects to Enter FY 2023 with

Ten or More Tolling Contracts. Believes Each Contract Could Generate $1 Million or More in PBI Revenue.

SOUTH EATON, MA / ACCESSWIRE / September 13, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" and the "Company"), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments, consumables, and specialty testing services to the worldwide life sciences, nutraceuticals, cosmetics, food & beverage, and other key industries, today announced the Company's participation in the September 12-14 H. C. Wainwright Annual Global Investor Conference. This conference will feature a number of exciting, rapidly-growing public and private companies, presenting for 30 minutes each. PBI's President and CEO, Mr. Richard T. Schumacher, will be speaking on September 13th at 1:30 pm ET.

Over the past four months, PBI has announced the execution of three agreements covering the production, distribution, commercial roll-out, and financial partnership for novel, effectively water-soluble, highly bioavailable, nanoemulsified CBD products for both oral and topical use. Recently, the Company also announced the execution of a cosmeceuticals partnership with Dr. Denese SkinScience, a 20-year skincare industry leader with over $500 million in QVC sales.

All four contracts are based on the use of the Company's patented, Ultra Shear Technology™ (UST™) platform to develop nanoemulsions of oil-based nutraceuticals and cosmetics. Nanoemulsions are known to turn oil-based active ingredient mixtures (e.g., CBD, THC, Astaxanthin, Curcumin, Retinol, Prednisone) into long-term stable, effectively water-soluble, highly bioavailable formulations. The Company believes these four contracts alone could generate over $5 million of accretive revenue for PBI in 2023. The Company plans to close on a minimum of six additional contracts over the remaining months of FY 2022.

DATE: Tuesday, September 13, 2022 (1:30 pm ET)

PRESENTATION: Video Webcast - Presentation plus Q&A

REGISTER: Link to PBIO Presentation - HCW Investor Conf.

Highlights of PBI's Recent Press Releases on the Launch of UST-Processed, Nanoemulsified CBD and Cosmeceutical Products - with Estimated Annual 2023 Revenue to PBI Expected to Exceed $5,000,000:

PBI has executed three contracts that call for the Company to manufacture thousands of liters of UST-processed CBD nanoemulsion bulk material during Q4 2022
CBD bulk nanoemulsion material will be sent to the Company's contractors who will vial, label, sell, and distribute the material via their e-commerce sites, sub-distributors, and other established sales channels
These unique products are expected to be long-term stable, effectively water-soluble, highly bioavailable nanoemulsions of CBD for oral and topical use
Formulation of the initial products has been completed: only plant-based reagents are used in the products
Safer Medical of Montana (SMM), Canopy CBD Farms (CCF), and North Star Holdings (NSH) will partner with PBI on production, distribution, commercial roll-out, and financial returns - terms of these partnerships are in agreements that were recently executed by the companies and PBI
These companies have distribution channels and infrastructure for their current health & wellness products
PBI believes first-year sales (FY 2023) will meet or exceed $5M in revenue for PBI
PBI believes no other CBD product on the market can compete with the quality of its UST-processed Nano-CBD
PBI has also announced a partnership with Dr. Denese SkinScience to manufacture new and to enhance existing skincare products sold under the Dr. Denese label. UST-processed products are expected for FY 2023 release.

[noshorthere]

Cosmetics deal, hell. That's vaporware. Per the PR: "Statements of Work ("SOW") will be developed, with approved budgets, timetables, and remuneration formulas for both companies."

In other words, they agree to negotiate an agreement at a later date.

Everything about PBIO and their "Partners" is flim-flam. The CEO of Safer Medical of Montana is a convicted counterfeiter. Another CEO , John Kaweseki of North Star Holdings: “According to the order, the case revolves around Clover Top Holdings, Inc. and its founder John Kaweske. The order states that in 2015 Kaweske and two other partners incorporated Clover Top Holdings, Inc. in Delaware with a principal place of business in Colorado to engage in the cannabis business. They are being sued by investors in Clover Top; the court describes the victims as self-described “victims of fraud, theft, and mismanagement.”....”The order states that Kaweske simultaneously created a competing marijuana operation that received ownership of the assets that originally belonged to or were intended to belong to Clover Top Holdings. According to the order, Kaweske and one of Clover Top Holdings’ investors, Manuel Evangelista, transferred Clover Top Holding’s assets and subsidiaries to several other entities.” Hmmmmm. That competing marijuana operation would be North Star Holdings.

https://brokercheck.finra.org/individual/summary/2309807 “FINRA has barred this individual (Kaweske) from acting as a broker or otherwise associating with a broker-dealer firm.”

https://www.offshorealert.com/tag/john-kaweske/ “Fresh from the collapse of his fraudulently operated Cayman Islands based stock brokerage SEGOES Securities with a net insolvency of approximately $10 million, John Kaweske, Jr. has re emerged in recent months through the creation of his own fantasy world” …. “The liquidators of offshore stockbroker SEGOES Services Ltd. have obtained a court judgment for US$3.9 million against the firm's principal director, John Kaweske, Jr.”

Sounds like Mr Kaweske (North Star Holdings, et al) and George S. Ackerson (Safer Medical Montana, et al) both graduated from the same Bogus Business School, and majored in bad business ethics.

[noshorthere]

According to one website, buzzfile.com (as of 2022): "This organization has been operating for approximately 3 years. Canopy CBD Farms is estimated to generate $39,710 in annual revenues, and employs approximately 4 people at this single location." This deal is about using the CanopyFarms CBD processing authority because as it turns out PBIO never had authority to prcess CBD.

[AveragePenny]

$PBIO Pressure BioSciences Secures Pivotal Cosmeceuticals Partnership for UST Platform With Dr. Denese SkinScience, 20-Year Leader With Over $0.5 Billion in QVC Sales

https://www.accesswire.com/713303/pressure-biosciences-secures-pivotal-cosmeceuticals-partnership-for-ust-platform-with-dr-denese-skinscience-20-year-leader-with-over-05-billion-in-qvc-sales

SOUTH EASTON, MA / ACCESSWIRE / August 24, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty testing services to the worldwide cosmetics, nutraceuticals, biotherapeutics, and food/beverage industries, among others, today announced the Company's agreement to team with science-driven skincare industry leader Dr. Adrienne Denese, M.D., Ph.D., the creator and President of Dr. Denese SkinScience - one of the most successful, highly rated, award winning, and longest lasting skincare lines in the history of QVC.

Under the two-year Collaborative Research and Development Agreement ("CRA") between PBI and Dr. Denese SkinScience, the two companies will prioritize specific skincare projects to pursue. Statements of Work ("SOW") will be developed, with approved budgets, timetables, and remuneration formulas for both companies. PBI and Dr. Denese have already agreed to focus on the use of PBI's unique Ultra Shear Technology™ ("UST™) nanoemulsification platform to enhance existing and develop new skincare products for Dr. Denese SkinScience. The UST platform's proven ability to process oil-based active ingredients (e.g., retinol, vitamins, anti-oxidants) into effectively water-soluble formulations is expected to offer more effective absorption, bio-availability, and therapeutic benefits to users of Dr. Denese SkinScience existing and new quality-leading skincare products.

Dr. Adrienne Denese commented: "Having achieved over $560 million in QVC sales over a 20-year period, I am very proud of our company's track record, my team, and the very loyal customer base that we have built under the Dr. Denese SkinScience brand. My mission has always been to develop and deliver the highest quality skincare products with life-changing effectiveness. Therefore, I could not be more excited at the prospect of teaming up with PBI and putting their UST platform's remarkable breakthrough in nanoemulsion effectiveness to work, in new generations of skincare products. I believe our partnership offers the opportunity to make new category-changing products that I have dreamed about, to enhance selected existing products, and to take these revolutionary new products to much greater heights and to many new customers through our existing QVC, e-commerce, and Amazon channels, as well as through our new Costco affiliation."

Mr. Richard T. Schumacher, President and CEO of PBI, observed: "From 2019 - 2021, Dr. Denese averaged close to $20 million per year in total sales. In 2022, with help from new channel partner Costco, sales are expected to increase significantly. The launch of a new generation of products processed by PBI's patented UST platform, for the first-time ever in the cosmeceuticals area, is planned for 2023, which we expect to result in a very fulfilling and exciting year for Dr. Denese and her loyal customers - and for PBI!"

Mr. Schumacher concluded: "Although final determination of the order of development of these new and enhanced products is yet to be announced, both Dr. Denese SkinScience and PBI understand that these are potential game-changers in an industry whose 2021 global market size was estimated to be over $130 billion. We look at this partnership as an opportunity for multi-million dollar accretive revenue growth for both companies over the next two years, with the potential to dramatically enhance the growth trajectory and profitability of both Dr. Denese SkinScience and PBI for years to come."

Mr. Jeffrey N. Peterson, Chairman of the PBI Board, added perspective: "Dr. Adrienne Denese is an accomplished doctor, scientist, businesswoman, and skincare visionary. Her life's mission has been to help women look and feel younger, and to live heathier lives. We noted from the outset of our work with Dr. Denese, that her immutable priority has always been to effectively provide the highest quality therapeutic ingredients to her customers. Through hard-work, tenacity, and an innate ability to deliver what the market needs, Adrienne has created a skincare line that has already become a titan in its field, as one of QVC's most successful, highly rated, award winning and longest lasting skincare lines. It continues to enjoy some of the highest rates of repeat, any-time, and automatic customer reorder rates of skincare products in QVC's history."

Mr. Peterson concluded: "Our UST platform is a transformational technology that we believe will alter the basis of competition for products across many industries, as it becomes the new manufacturing standard in cosmeceuticals and other industries. For our initial entry into the cosmeceuticals and personal care products sector, it was important that we partnered with an industry leader driven by science. Dr. Denese fulfilled that promise, with products sold not just in the U.S., but throughout the world. She is a visionary, innovator, and global success story. We are honored to partner with her and her amazing team. As the first cosmeceuticals company to embrace and capitalize on the powerful advantages of the UST platform for nanoemulsions processing, Dr. Denese SkinScience continues to deliver visionary leadership in setting unrivaled standards for quality and performance - a potent example for UST impact that will resonate across industries."

[MJ410]

Keep seeing posts about this company in a FB group.

Anyone have any good info?

[AveragePenny]

$PBIO Pressure BioSciences Announces Contract for October 2022 Launch of Breakthrough Hemp-Derived CBD Product, Estimating $2 Million Incremental 2023 Revenue

https://www.accesswire.com/712609/pressure-biosciences-announces-contract-for-october-2022-launch-of-breakthrough-hemp-derived-cbd-product-estimating-2-million-incremental-2023-revenue

Canopy CBD Farms, with Multiple Sales Channels and Industry Contacts Nationwide, Partners with PBI to Commercialize Revolutionary Hemp-Derived CBD Product, Offering Unparalleled Topical Effectiveness

SOUTH EASTON, MA / ACCESSWIRE / August 18, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty testing services to the worldwide nutraceuticals, biotechnology, cosmetics, and food & beverage industries, today announced the execution of a manufacturing, sales, and distribution agreement with Canopy CBD Farms, LLC ("CCF"), a Massachusetts licensed processor/manufacturer/distributor of hemp-derived CBD products and processing equipment. CCF, with a strong focus in the Massachusetts/New England hemp-derived CBD market and with hundreds of industry connections nationwide, has assembled an aggressive distribution plan that anticipates nano-CBD product sales (both in bulk and end-user packaging) of nearly $6 million over the first 12-months post-release. Under GAAP rules/standards, PBI believes it will capture approximately $2 million of CCF's expected product revenue.

PBI recently announced the commercial launch of its patented Ultra Shear Technology™ ("UST™") nanoemulsion processing platform. The Company will manufacture and sell - through a tolling processing center located in their South Easton MA facility - revolutionary, effectively water-soluble, hemp-derived nanoemulsions, in bulk format. PBI's USDA compliant nano-CBD is expected to introduce a new generation of precise and efficient CBD dosing in a wide variety of shelf-stable, clean-label (containing no chemical preservatives) products, encompassing the nutraceuticals, personal care products, cosmetics, and food/beverage markets, to name a few. Following production at PBI, bulk nano-CBD product will be sent to CCF or its designated production facility, where it will be vialed and labelled, and then made available for sale. CCF also plans to sell bulk nano-CBD product to other manufactures for use in their own product line ("white labelling").

Mr. John Westlake, Founder and President of CCF, explained, "There is an enormous unmet need in the hemp-derived CBD marketplace for USDA-compliant products manufactured from high quality, highly water soluble nanoemulsions containing only natural ingredients. This is what has now been uniquely enabled by PBI and their patented UST nanoemulsification platform. Frankly, this is exactly what I have been waiting for: a line of plant-based, hemp-derived CBD products that contain no artificial ingredients, while achieving breakthroughs in effectiveness and long-term stability.

Mr. Westlake continued: "Using the sales and distribution channels that I have spent years developing, augmented with my vast number of contacts in the industry, I am confident that USDA-compliant nano-CBD products processed by PBI's UST platform, will not just sell well, but will set new standards of performance that others will struggle to meet. I expect that CCF's first year revenue projection of $6 million will be mostly generated in New England, with major additional revenue growth to follow as we expand distribution throughout the rest of the U.S."

Mr. Kenneth F. Micciche, Director of Business Development at PBI, commented: "Our PBI team is incredibly excited as we now transition into production of UST-based products and what we believe will be impressive and highly profitable product revenues in late 2022, then accelerating into 2023 and beyond. Our team has demonstrated focus, commitment, and resolve in completing the development of a world-class, patented method for processing hemp-derived CBD into the highest quality, commercial grade nanoemulsions available today. This achievement allows PBI to immediately begin to work with CCF to help them leverage their impressive industrial network and connections to dispensaries, eCommerce, and other channel partners, as they use the UST competitive advantage to drive revenue growth in this estimated $16.6 billion market."

Mr. John B. Hollister, PBI's Director of Marketing and Sales, concluded: "Our partnership with CCF demonstrates more broadly PBI's commitment to diverse customers seeking innovative, effectively water-soluble delivery of important oil-based products that actually meet and exceed the high levels or performance expected by today's sophisticated consumers. The CCF and the two other product agreements announced recently are collectively expected to generate an estimated $4 million in incremental revenue for PBI in 2023 - and we expect to announce even more significant contracts shortly."

PBI Quarterly Investor Call: Thursday, August 18, 2022

The teleconference will include a Company presentation followed by a Question & Answer period. Date: Thursday, August 18, 2022. Time: 4:30 PM Eastern Time (ET). To attend this teleconference, live by telephone: Dial-in: [phone] (North America); [phone] (International). Verbal Access Code: 264516 (or say PBI Q2 Conference Call). For those unable to participate in the live teleconference, a replay will be available beginning Friday, August 19, 2022. The replay will be accessible via telephone and PBI's website for 30 days. Replay Number: [phone] (North America); [phone] (Int'l); Replay Passcode: 46409.

[AveragePenny]

$PBIO Pressure BioSciences, Inc. to Discuss Second Quarter 2022 Financial Results and Provide Business Update

https://www.accesswire.com/712402/pressure-biosciences-inc-to-discuss-second-quarter-2022-financial-results-and-provide-business-update

Conference Call Scheduled for Thursday August 18 at 4:30pm ET

SOUTH EASTON, MA / ACCESSWIRE / August 16, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" and the "Company") today announced that the Company will host a teleconference to discuss its Second Quarter 2022 financial results and to provide a business update. Anyone interested may listen to the teleconference either live (by telephone) or through a replay (by telephone or via a link on the Company's website) approximately one day after the teleconference.

The teleconference will include a Company presentation followed by a Question & Answer period.

Date: Thursday, August 18, 2022.
Time: 4:30 PM Eastern Time (ET).

To attend this teleconference, live by telephone: Dial-in: [phone] (North America); [phone] (International). Verbal Access Code: 264516 (or say Pressure BioSciences Q2 Conference Call)

For those unable to participate in the live teleconference, a replay will be available beginning Friday, August 19, 2022. The replay will be accessible via telephone and the Company's website for 30 days.

Replay Number: [phone] (North America); [phone] (Int'l); Replay Passcode: 46409.

[resx18]

SOUTH EASTON, MA / ACCESSWIRE / August 11, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty testing services to the worldwide biopharmaceuticals, nutraceuticals, cosmetics, agrochemical, and food & beverage industries, today announced approval for its South Easton MA facility to manufacture custom, compliant, hemp-derived CBD nanoemulsions under the processing/manufacturing license of its commercial partner, Canopy CBD Farms, Fitchburg, MA.

Canopy CBD Farms ("CCF") is a Massachusetts licensed hemp processing and manufacturing company. Foreseeing the future of government regulations, CCF has strategically aligned itself with established FDA registered laboratories and manufacturers to bring the highest of standards and quality of hemp-derived CBD products. Canopy CBD Farms serves pharmaceutical and medical research companies, wishing to establish white label/co-branded manufacturing partnerships with cGMP, GLP manufacturers. CCF's partnerships will increase wholesale and retail distribution channels, with a ready-to-label line of high quality, salable hemp-derived CBD products, for a variety of uses and industries.

Mr. John Westlake, Founder and President of CCF, commented, "I am delighted to partner with PBI by extending my CBD processing and manufacturing license to PBI's South Easton location. I firmly believe I can leverage my many years in the cannabis market and hundreds of industry connections to help PBI get quickly and efficiently to market with their unique, highly stable, and water-soluble hemp-derived CBD nanoemulsions, processed using their world-class UST platform."

Using the Company's patented Ultra Shear Technology™ ("UST™") platform, PBI will manufacture and sell - through a tolling processing center located in their South Easton MA facility - a new generation of effectively water-soluble hemp-derived CBD nanoemulsions, in bulk format. Expected to be purchased primarily by formulators and manufacturers, both in MA and throughout the U.S., PBI's nano-CBD is expected to introduce revolutionary precise and efficient dosing of hemp-derived, nanoemulsified CBD in a wide variety of shelf-stable, clean-label (containing no chemical preservatives) products, encompassing the nutraceuticals, personal care products, cosmetics, and food/beverage markets, to name a few.

Mr. Kenneth F. Micciche, Director of Business Development at PBI, stated: "We are thrilled that our facility has been inspected and approved by the Mass. Dept. of Agricultural Resources ("MDAR"). We can now begin a new phase for our business, to produce and deliver the finest available water-soluble hemp-derived CBD nanoemulsions for use in thousands of products, in MA and throughout the U.S. We believe our nano-CBD will deliver unprecedented up-take, quality, potency, and reliable dosage control and delivery. CCF's MDAR license - required to process hemp-derived CBD in MA - enables PBI to begin to fulfill the customer demand and signed production contracts that we previously announced, and the many new ones to come, for the highest quality CBD nanoemulsions in a global market estimated to reach $16.6 billion by 2027."

Mr. Richard T. Schumacher, President and CEO of PBI summarized: "We believe our UST technology platform, coupled with CCF's license to process/manufacture in MA and John's impressive experience and remarkable contacts in the cannabis field, will greatly support the launch of our tolling service model, driven by the delivery of high value, UST-processed CBD nanoemulsion products that provide an improved experience derived from enhanced quality and bioavailability."

[AveragePenny]

$PBIO Pressure BioSciences Announces Approval to Manufacture Hemp-Derived CBD Products in Massachusetts, Including Their Revolutionary CBD Nanoemulsions

https://www.accesswire.com/711740/Pressure-BioSciences-Announces-Approval-to-Manufacture-Hemp-Derived-CBD-Products-in-Massachusetts-Including-Their-Revolutionary-CBD-Nanoemulsions

Canopy CBD Farms, MA-licensed North American Processor/Manufacturer/Distributor of CBD Products Derived from Hemp, Received State Approval Covering PBI's Manufacture of CBD Nanoemulsions for Sale to MA and Nationwide Formulators and Manufacturers of Hemp-Derived CBD Products

SOUTH EASTON, MA / ACCESSWIRE / August 11, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty testing services to the worldwide biopharmaceuticals, nutraceuticals, cosmetics, agrochemical, and food & beverage industries, today announced approval for its South Easton MA facility to manufacture custom, compliant, hemp-derived CBD nanoemulsions under the processing/manufacturing license of its commercial partner, Canopy CBD Farms, Fitchburg, MA.

Canopy CBD Farms ("CCF") is a Massachusetts licensed hemp processing and manufacturing company. Foreseeing the future of government regulations, CCF has strategically aligned itself with established FDA registered laboratories and manufacturers to bring the highest of standards and quality of hemp-derived CBD products. Canopy CBD Farms serves pharmaceutical and medical research companies, wishing to establish white label/co-branded manufacturing partnerships with cGMP, GLP manufacturers. CCF's partnerships will increase wholesale and retail distribution channels, with a ready-to-label line of high quality, salable hemp-derived CBD products, for a variety of uses and industries.

Mr. John Westlake, Founder and President of CCF, commented, "I am delighted to partner with PBI by extending my CBD processing and manufacturing license to PBI's South Easton location. I firmly believe I can leverage my many years in the cannabis market and hundreds of industry connections to help PBI get quickly and efficiently to market with their unique, highly stable, and water-soluble hemp-derived CBD nanoemulsions, processed using their world-class UST platform."

Using the Company's patented Ultra Shear Technology™ ("UST™") platform, PBI will manufacture and sell - through a tolling processing center located in their South Easton MA facility - a new generation of effectively water-soluble hemp-derived CBD nanoemulsions, in bulk format. Expected to be purchased primarily by formulators and manufacturers, both in MA and throughout the U.S., PBI's nano-CBD is expected to introduce revolutionary precise and efficient dosing of hemp-derived, nanoemulsified CBD in a wide variety of shelf-stable, clean-label (containing no chemical preservatives) products, encompassing the nutraceuticals, personal care products, cosmetics, and food/beverage markets, to name a few.

Mr. Kenneth F. Micciche, Director of Business Development at PBI, stated: "We are thrilled that our facility has been inspected and approved by the Mass. Dept. of Agricultural Resources ("MDAR"). We can now begin a new phase for our business, to produce and deliver the finest available water-soluble hemp-derived CBD nanoemulsions for use in thousands of products, in MA and throughout the U.S. We believe our nano-CBD will deliver unprecedented up-take, quality, potency, and reliable dosage control and delivery. CCF's MDAR license - required to process hemp-derived CBD in MA - enables PBI to begin to fulfill the customer demand and signed production contracts that we previously announced, and the many new ones to come, for the highest quality CBD nanoemulsions in a global market estimated to reach $16.6 billion by 2027."

Mr. Richard T. Schumacher, President and CEO of PBI summarized: "We believe our UST technology platform, coupled with CCF's license to process/manufacture in MA and John's impressive experience and remarkable contacts in the cannabis field, will greatly support the launch of our tolling service model, driven by the delivery of high value, UST-processed CBD nanoemulsion products that provide an improved experience derived from enhanced quality and bioavailability."

[AveragePenny]

$PBIO Pressure BioSciences Doubles Growth Projections for UST Nanoemulsion Contracts Following Clear Confirmation of Unmet Needs in Exploding Cannabis Drinks Sector

https://www.accesswire.com/710984/pressure-biosciences-doubles-growth-projections-for-ust-nanoemulsion-contracts-following-clear-confirmation-of-unmet-needs-in-exploding-cannabis-drinks-sector

Conferences on West Coast and Midwest Illuminate Rapid Market Expansion of Cannabis Beverages and Critical Role for UST Nanoemulsions to Revolutionize Effective Precision Dosing and Delivery

SOUTH EASTON, MA / ACCESSWIRE / August 5, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty testing services to the worldwide biopharmaceuticals, nutraceuticals, cosmetics, agrochem, and food/beverage industries, today announced that its participation at the recent San Francisco and Chicago Cannabis Drinks Expos produced over 60 strong leads for prospective contracts serving the cannabis beverages sector. The need for more effective delivery of cannabis dosing quickly and with reliably repeatable precision was a nearly universal theme reinforced across two days of meetings with companies already active in or entering the $2 billion cannabis beverage market. Among these leads, seven companies requested immediate discussions and follow-up on the potential for incorporating PBI's patented Ultra Shear Technology™ (UST™) platform for the nanoemulsification of CBD and other cannabinoids into their cannabis product lines as quickly as possible.

Mr. Kenneth F. Micciche, PBI's Director of Business Development, commented: "PBI's patented UST platform is a unique breakthrough nanoemulsification system designed to resolve one of the most significant problems facing manufacturers of cannabis infused beverages today: the extremely poor solubility of cannabis-derived oils (e.g., CBD) in water. Poor water solubility results in poor bioavailability of the oil-based cannabinoid (CBD, CBG, CBN, THC, etc.), results in unreliable and variable dosing and response times, and deprives the consumer of the ability to enjoy the full benefits of the cannabis active ingredients for which they are paying."

As with any oil-based product, it is difficult for the water-based biochemistry of humans and other animals to access and absorb active ingredients hidden within oil droplets at the scale delivered by many current "nanoemulsion" technologies. The natural immiscibility of oil and water inhibits effective water solubility and absorption of oil-based components, resulting in poor and unpredictable bioavailability of active ingredients. This makes it exceedingly difficult to design and deliver proper dosing of the desired active ingredients. Scientific data have repeatedly shown that oil-based active ingredients manufactured into high quality nanoemulsions with consistent, low nano-droplet sizes have produced dramatically faster and reliably complete amounts of cannabinoids (and other oil-based active components). This revolution in absorption and bioavailability delivers higher quality and more desirable finished products for the consumer.

Mr. John B. Hollister, Director of Sales and Marketing at PBI, reflected on PBI's participation in these two cannabis drinks expositions: "With our proven ability to deliver what we believe to be the highest quality nanoemulsions of CBD and other cannabinoids worldwide, we had expected very positive meetings and engagement around UST. Frankly, these two expos vastly exceeded our expectations. The interest in our UST nanoemulsions platform kicked off with inquiries before the exhibits were even open and continued strong throughout each day and into the evening's activities. We had dozens of visitors to our booth, comprised of a wide variety of beverage manufacturers - including producers of beer, seltzers, soft drinks, juices, energy drinks, and water. Although these visitors were from various parts of the beverage industry, they all had one thing in common - they needed a reliable method to provide fast and accurate dosing of CBD and other cannabinoids for infusion into their drinks."

Mr. Hollister continued: We identified over 60 booth visitors as highly qualified leads. Some were groups doing substantial business who quickly understood the benefits of the UST process; others were companies about to initiate production; still others were well-funded start-ups. Of these many leads, seven pressed strongly for immediate follow-up, including three who proposed working towards setting up UST nanoemulsion processing for cannabinoids in their own laboratories in 2023."

Mr. Richard T. Schumacher, President and CEO of PBI, summed up: "This was our first time participating in cannabis-focused expositions - and it was a resounding success! Last month we announced our plan and forecast to have a minimum of six UST nanoemulsion toll-processing contracts in place by the close of 2022. Based on the immediate traction gained in these two cannabis beverage meetings, and the feedback to date from our Consortium colleagues at The Ohio State University focusing on UST introductions and rapid penetration into the Food and Beverages industry, we have increased our guidance to a total of twelve UST contracts to be closed by the end of 2022. We believe that each of these new contracts will offer $1M or more per year in incremental revenue to PBI in 2023 and beyond."

[noshorthere]

Google John Kaweske, CEO of North Star Holdings. You'll see a crooked history that rivals the CEO of Safer Medical of Montana, PBIO's other contract.

It's telling that the only companies signed up with PBIO are run by criminals, and are in the cannabis business.

[AveragePenny]

$PBIO Pressure BioSciences Announces Second Contract for Toll Manufacturing of a CBD Nanoemulsion Product Using Its Proprietary Ultra Shear Technology Platform

https://www.accesswire.com/709316/pressure-biosciences-announces-second-contract-for-toll-manufacturing-of-a-cbd-nanoemulsion-product-using-its-proprietary-ultra-shear-technology-platform

PBI Partners with Leading Colorado Cannabis Company for Manufacture and Distribution of Novel Nano-CBD Topical Spray and Other Products, Anticipating $2 Million in 2023 Revenue Contribution

SOUTH EASTON, MA / ACCESSWIRE / July 21, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty testing services to the worldwide nutraceuticals, biotherapeutics, cosmetics, and food/beverage industries, among others, today announced its agreement signed with North Star Holdings ("NSH") on their financial partnership for the development, production, distribution and commercial roll-out of NSH's novel, effectively water-soluble, nanoemulsified CBD spray for topical use. NSH's roll-out and distribution plan for the nano-CBD topical spray conservatively estimates revenues of approximately $1.5M in 2023. PBI will also partner with the NSH team on the development and distribution of additional nano-CBD containing products that the highly successful Colorado cannabis operator has already suggested. NSH believes it could generate an additional $4.5M in revenue from these nano-CBD containing products in 2023. Under the terms of the contract, PBI expects to receive about one-third of total product revenue. This is the second contract recently announced by PBI for financial partnership in the toll manufacturing and subsequent distribution of non-PBI products, based upon an independent company's use of nano-CBD generated from PBI's patented Ultra Shear Technology™ (UST™) processing platform.

North Star Holdings, Inc., founded in 2015 and based in Colorado Springs, is a rapidly growing, vertically-integrated, multi-state enterprise-level cannabis operator in states where medical and/or adult-use cannabis is legal. NSH owns 13 dispensary licenses in Colorado, owns thousands of square feet of cultivation and manufacturing facilities, and has a highly effective network of wholesale and retail product marketing and distribution channels. In 2021, NSH's revenue topped $18 million.

Mr. John Kaweske, President and CEO of NSH, commented: "The Cannabis Industry now intimately understands that the differentiation of high quality and effective bioavailability for oil-based active ingredients like CBD and other cannabinoids in consumer-friendly clean-label products (without undesirable additives) requires processing into long-term stable, highly water-soluble nanoemulsions that achieve extremely low droplet sizes. I have been in this industry for a decade, distributing a large number of products from all over the U.S. and selling many millions of dollars of cannabinoid products annually. I have detailed, first-hand knowledge of the relative positioning and success of the products in the marketplace. In my experience, there are very few - if any - high-performance products containing true CBD nanoemulsions available in the market today, due to the limitations and compromises implicit in current nanoemulsion production technologies."

Mr. Kaweske continued: "I am extremely excited to partner with PBI, because their UST-produced nano-CBD is unrivaled in its proven ability to achieve consistent, ultra-low droplet size nanoemulsions that deliver unmatched stability, effective water-solubility, and the resulting benefits expected in dosage control, fast delivery, and bioavailability. I believe the products that NSH will help produce and then market containing UST-processed nano-CBD have great potential to become standard-setters in the markets that we serve."

Mr. Richard T. Schumacher, President and CEO of PBI, added: "John's years of experience in the cannabis space, his highly successful and vertically-integrated state-wide enterprise, and his company's rapid growth over the past seven years to nearly $20 million in annual revenue is very impressive. John has already delivered highly valuable perspectives and strategies that we believe will help NSH get their new nano-CBD topical product to market faster and more efficiently than could have happened had we partnered with anyone else. This is a tremendous opportunity for both NSH and PBI, one that we believe will generate several million dollars in annual revenues for PBI in 2023, with exciting, accelerating growth into the future."

PBI's Chairman, Mr. Jeffrey N. Peterson put this in strategic context for PBI: "Emerging from intense multi-year R&D on UST, our team has recently completed a thoughtful 3-year plan for PBI, prioritizing funding and investment to accelerate commercialization of the UST platform. Our early emphasis on toll manufacturing partnerships allows us to participate more deeply in the strategic positioning and differentiation of diverse UST-enabled nanoemulsion products. It also allows PBI to participate in the financial upside of this powerful technology affecting a multitude of multi-billion-dollar markets, spanning nutraceuticals, pharmaceuticals, cosmetics and personal care products, as well as food and beverages, agrochemicals and more. We believe the commercialization of the UST platform offers a revolutionary growth and financial performance breakout for PBI that will result in the achievement of financial breakeven in 2023 and accelerating profitability beyond. We will continue to apprise investors on further contract negotiations being closed and our growth acceleration in the coming days and weeks."

[noshorthere]

There you go----an earth rotation reversing announcement....Wait a minute isn't Safer Medical a company with about $4.8M revenue per year? That $3M "target" represents more than a 60% increase in revenue for an untried product. And, are you sure you want to trust the word of a CEO who, as an Officer and helicopter pilot in the U.S. Army was court-martialed, and later (as a civilian) was convicted of counterfeiting and also has control of a couple of dubious 501-c3 corps funded by SMM, that the $3M "target" is real and do-able?

[AveragePenny]

$PBIO Pressure BioSciences to Expand on Upcoming Release of CBD Nanoemulsion Oral Spray at July 6th Emerging Growth Conference - Annual Revenue to PBI Expected to Exceed $1M

https://www.accesswire.com/707664/pressure-biosciences-to-expand-on-upcoming-release-of-cbd-nanoemulsion-oral-spray-at-july-6th-emerging-growth-conference-annual-revenue-to-pbi-expected-to-exceed-1m

Company Invites Investors, Analysts, and Advisors to Attend Its Real-Time, Interactive Update/Q&A Session

SOUTH EASTON, MA / ACCESSWIRE / July 6, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" and the "Company"), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments, consumables, and specialty testing services to the worldwide life sciences, nutraceuticals, cosmetics, food & beverage, and other key industries, today announced the Company's participation in the July 6th Emerging Growth Investor Conference. This real-time, interactive conference will feature a number of exciting, rapidly-growing publicly traded companies, presenting for 30-45 minutes each. PBI's President and CEO, Mr. Richard T. Schumacher, will be speaking at 10:30 am ET. Mr. Schumacher will briefly expand on the Company's recent announcement of its contracted production launch of its first UST-processed commercial product: a nanoemulsified CBD aerosol spray for oral use.

Last week, PBI announced the execution of an agreement with Safer Medical of Montana ("SMM") covering the production, distribution, commercial roll-out, and financial partnership for a novel, effectively water-soluble, nanoemulsified CBD spray for oral use. SMM's roll-out and distribution plan targets revenues of $3M or more over the first 12-months post-release. Under this agreement, PBI expects to realize more than $1M in revenue from SMM's $3M sales target. This is the first commercial product produced and marketed that uses the Company's patented Ultra Shear Technology™ (UST™) platform.

DATE: Wednesday, July 6, 2022 (10:30 am ET)
PRESENTATION: Video Webcast - Presentation plus Q&A
REGISTER: Click here to register for the conference

Highlights of PBI's Recent Press Release on the Contracted Production Launch of a UST-Processed, Nanoemulsified CBD Spray for Oral Use - with Estimated Annual Revenue to PBI Expected to Exceed $1,000,000:

PBI will release its first ever UST-processed product to the U.S. market over the next few months
This unique product is a long-term stable, highly water-soluble CBD aerosol spray for oral use
Formulation of the product has been completed: only plant-based reagents are used in the product
Safer Medical of Montana (SMM) will partner with PBI on production, distribution, commercial roll-out, and financial returns - terms of this partnership are in an agreement that was recently executed by the companies
SMM has existing distribution channels and infrastructure for its current health and wellness products
SMM estimates that first-year sales will meet or exceed $3M with revenue of over $1M belonging to PBI
SMM believes no other CBD oral spray available today can compete with the quality and water absorbability of the PBI UST-processed nanoemulsified product

[AveragePenny]

$PBIO Pressure BioSciences Announces Contracted Production Launch for Estimated $3,000,000 of UST-Processed, Nanoemulsified CBD Spray for Oral Use

https://www.accesswire.com/706907/Pressure-BioSciences-Announces-Contracted-Production-Launch-for-Estimated-3000000-of-UST-Processed-Nanoemulsified-CBD-Spray-for-Oral-Use

Safer Medical of Montana, a Seasoned Distributor of Wellness Products with a Focus on Veterans, Partners with PBI as Exclusive Distributor for Highly Stable and Water-Soluble CBD Oral Aerosol Product

SOUTH EASTON, MA / ACCESSWIRE / June 29, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty testing services to the worldwide biotechnology, biotherapeutics, nutraceuticals, cosmetics, agrochem, and food/beverage industries, today announced its signed agreement with Safer Medical of Montana ("SMM") on production, distribution, commercial roll-out and financial partnership for a novel, effectively water-soluble, nanoemulsified CBD spray for oral use. SMM's roll-out and distribution plan targets revenues of $3M or more over the first 12-months post-release. Under the agreement, PBI expects to realize more than $1M in revenues from this $3M product sales target. This is the first commercial product being produced and marketed that incorporates the Company's patented Ultra Shear Technology™ (UST™) platform.

As announced last month, PBI and SMM have collaborated over the past year in the development of a proprietary formulation for this unique product. The companies have now completed formulation development and are securing the necessary approvals for production in the Commonwealth of Massachusetts and distribution throughout all of the United States. SMM's initial product will be an oral spray containing 40mg/mL of nanoemulsified CBD. The companies plan to release the new CBD oral spray product to consumers during the third quarter of 2022.

Mr. John B. Hollister, Director of Sales and Marketing at PBI, observed: "This SMM agreement launches an exciting new chapter in the evolution of PBI. Building on our deep expertise in the safe applications of high-pressure technology, we are now preparing to release the first product prepared by UST - our truly revolutionary platform technology that shears oil-water emulsions down to extremely low and tightly-controlled nano-sized oil droplets. The commercialization of UST throws open the door to countless applications in diverse multi-billion-dollar markets where effective water-solubility of oil-based active ingredients is critical for optimized bioavailability and absorption - including cannabinoids, nutraceuticals, cosmetics, pharmaceuticals, food and beverages, agrochem, industrial lubricants, paints, and more."

Mr. Hollister continued: "The feedback we have received across many sample products created with UST has exceeded all expectations. The application of UST to provide greatly improved delivery and functionality of oil-based active materials and products via nanoemulsification offers enormous potential to translate into a diverse array of major commercial opportunities for our partners and for PBI, while benefitting and redefining product expectations for consumers worldwide."

Captain George Ackerson, Founder and CEO of SMM, shared his plans: "With this partnership and distribution agreement in place, our mission is now on the successful launch of the nanoemulsified CBD oral spray. This launch includes a key focus on accessing U.S. veterans, a group we believe will benefit greatly from this innovative product. We are reaching out to the Veterans Administration and developing plans to work with the not-for-profit Veteran Seal Team, Inc. ("VST"). In addition to direct sales through our website, we are setting up distribution with a network of nurses who specialize in the needs of veterans."

Captain Ackerson continued: "SMM has been distributing wellness products for many years, giving us significant experience in the best ways to get novel, breakthrough products into the hands of consumers. The PBI partnership is built upon estimated first-year sales of over $3 million dollars, to be achieved through three planned phases of roll-out at increasing scale. With our current and planned distribution channels, we believe this goal is more than attainable."

Mr. Richard T. Schumacher, President and CEO of PBI, summed up: "This first UST commercialization and partnering agreement with Captain Ackerson and Safer Medical of Montana is a pivotal transition moment in the history of PBI. We are expecting to announce significant additional agreements in the very near future, specifically in markets with an expected quick ramp to revenue, such as cosmetics, agrochem, and nutraceuticals. We also believe that our co-leadership role in the Food Industry Consortium with partner The Ohio State University, whose mission is to introduce the UST platform to food and beverage companies worldwide, will soon result in additional revenue-generating agreements. We expect that the substantial revenue expected from these future agreements will accelerate balance sheet improvements and help finance PBI's operations, investments, growth, and trajectory to profitability before the end of 2023."

[AveragePenny]

$PBIO Pressure BioSciences' Ultra Shear Technology Positioned for Critical Enabling Role in Global $41 Billion (2027) Plant Protein Beverage Market

https://www.accesswire.com/705013/pressure-biosciences-ultra-shear-technology-positioned-for-critical-enabling-role-in-global-41-billion-2027-plant-protein-beverage-market

Recent Study Published by The Ohio State University Illuminates Unique Capabilities of PBI's UST Platform for Optimal Formulation and Processing of New and Existing Plant Protein-based Beverages

SOUTH EASTON, MA / ACCESSWIRE / June 14, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and process development services to the worldwide food and beverage, biotherapeutics, and personal wellness industries, among others, today announced a pivotal peer-reviewed scientific publication highlighting the use of PBI's patented Ultra Shear Technology™ ("UST™") platform in the production of protein-enriched milk containing a novel emulsified plant-protein suspension. J.J. Janahar, et al., from The Ohio State University ("Ohio State") College of Food, Agricultural, and Environmental Sciences ("CFAES") in a study published in the high impact journal Food Hydrocolloids, Volume 131, reported that UST successfully created stable suspensions of milk-pea protein blends in microscopic particle sizes - the objective required for commercially-suitable products, and a significant achievement that could not be reached through existing high-pressure processing (HPP) or thermal processing techniques alone.

Efforts to produce satisfying, nutritionally-efficient and sustainable food options are driving one of the fastest growing food and beverage markets worldwide. Creating cost-effective and sustainable food alternatives that appeal to the expectations and preferences of global consumers has pushed researchers to examine many alternative protein enrichment sources, including the use of almonds, oats, soy, coconuts, peas, etc. Unfortunately, many of these protein sources lack the creaminess, texture, sweetness, or other attributes that drive consumer acceptance. The blending of plant and dairy components to achieve the desired consumer appeal presents enormous market opportunities. Pea protein is of particular interest because of its high nutritional value and low cost - but it is highly insoluble in water and thus has been minimally used in protein drinks to date. PBI's proprietary UST platform combines very high pressure and precisely controlled extreme shear forces to provide food scientists the toolset needed to successfully blend dairy and pea protein (two products which naturally resist mixing) into a sensory-appealing, nutritional, and long-term stable plant protein-based beverage.

PBI and Ohio State are co-leading a Food Industry Consortium whose mission is to introduce worldwide food and beverage companies to PBI's UST platform for the production of higher quality, longer shelf-life, and safer liquid foods and beverages. PBI's UST platform is the critical tool that enables and achieves targeted reductions and dependency on chemical additives or damaging heat relied upon in current processing methods. UST is pivotal in enabling the production of natural, organic, healthier, more nutritious, "clean-label" products that offer greater appeal to modern consumers.

Mr. John B. Hollister, Director of Marketing and Sales expanded: "Ohio State and PBI have initiated an aggressive outreach program to a number of preeminent food & beverage companies globally and expect to welcome many Consortium members during the second half of 2022. Members will help direct and focus Ohio State and PBI efforts across a diverse universe of prospective liquid food and beverage products, with emphasis on microbiology, stability, nutrition, sensory qualities, and increased bioavailability. UST applications development will also extend into nutraceutical products, such as infused water, functional sports beverages, and other health-focused products of high interest to consumers and producers." (North Equities Video Interview - Hollister).

Mr. Hollister continued: "With the recent publication of the Ohio State data, an additional and very exciting application of interest is plant protein-based beverages. As new and commercially-relevant UST applications continue to be demonstrated, and Consortium members utilize their first rights to license UST for their own use, Ohio State and PBI will both benefit from resulting royalty streams. PBI will also benefit from equipment leases and consumables sales."

Dr. Edmund Y. Ting, Senior VP of Engineering at PBI, and a pioneer in the development of high pressure-based food technologies, commented: "Many beverage ingredients that are beneficial to convenience, health, and desired sensory characteristics are not soluble in water, e.g., pea proteins. However, UST's ability to achieve micro/nano particle size suspensions of such plant proteins offers enticing solutions for the use of these essential, water-insoluble ingredients. Interestingly, such UST-processed suspensions can be optimized to provide thickening viscosity for certain products, which can result in improved stability, nutritional value, and consumer appeal. Thus, UST's ability to formulate complex micro/nano emulsions and suspensions will give manufacturers multiple additional options for health and wellness products. While we have previously demonstrated that UST makes fantastic nanoemulsions, there are even more applications where microemulsions as well as nano/micro suspensions are practical and useful for products and product concentrates."

Mr. Richard T. Schumacher, President and CEO of PBI, summarized: "The quest for finding alternative beverages that are healthier and environmentally sustainable but also appealing to the palate - such as plant protein-based drinks - is a rapidly growing market estimated to reach $41B by 2027 (MDC Market Report). We are currently in discussions with industry leaders in this market, as well as companies that want to use UST to make high quality nanoemulsions to add vitamins, antioxidants, nutraceuticals, etc. to their beverages. The recent Ohio State results on UST-processed micro/nano plant protein milk suspensions, as well as previously released data om UST-enhanced nanoemulsions, support our confidence that UST has the potential to become an essential tool in future beverage development, as well as in other health-related and consumer markets (TechTalks Video). We continue to look forward to the planned Q3/Q4 2022 commercial release of the UST platform."

Sponsorship of UST development by the U.S. Department of Agriculture's NIFA program is deeply appreciated.

[AveragePenny]

$PBIO Emerging Technology Insider Releases New TechTalks Video Interview with Pressure BioSciences' CEO Richard T. Schumacher


https://www.accesswire.com/702465/emerging-technology-insider-releases-new-techtalks-video-interview-with-pressure-biosciences-ceo-richard-t-schumacher

SOUTH EASTON, MA / ACCESSWIRE / May 24, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" and the "Company") today announced that Emerging Technology Insider, a leading global source for business and financial opportunities of technology companies, has released a new TechTalks video interview featuring Richard T. Schumacher, CEO and Founder of Pressure BioSciences, Inc.

PBI is a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty testing services to the worldwide biotechnology, biotherapeutics, nutraceuticals, cosmetics, agriculture, and food/beverage industries. The interview focused on PBI's recent initiation of an Early Access Program for its revolutionary Ultra Shear Technology™ ("UST™") platform for the processing of oil-based active ingredients into water soluble, highly bioavailable, long-term stable nanoemulsions.

The TechTalks video can be viewed at www.EmergingTechnologyInsider.com. It can also be accessed through the following link: TechTalks.PBI.052422.

[AveragePenny]

$PBIO Pressure BioSciences to Present at the Planet MicroCap Showcase 2022 on May 4, 2022

https://www.accesswire.com/699902/pressure-biosciences-to-present-at-the-planet-microcap-showcase-2022-on-may-4-2022

Company Invites Investors, Analysts, and Advisors to Attend Its In-Person and Webcast Presentation on Wednesday, May 4, 2022 at 11:30am PDT

SOUTH EASTON, MA / ACCESSWIRE / May 3, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" and the "Company"), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments, consumables, and specialty services to the worldwide biopharmaceuticals, cosmetics, nutraceuticals, agrochem, and food & beverage industries, today announced the Company's participation as a presenter at the May 3-5 Planet MicroCap Showcase 2022. This on-site investor conference is being held at the Bally's Hotel and Casino in Las Vegas, Nevada, from May 3-5, 2022. The Conference will feature over 80 top public and private companies in the microcap space. In his presentation, PBI's President and CEO, Mr. Richard T. Schumacher, will expand on the Company's recent achievements in the nanoemulsification of CBD and other cannabinoids, as well as with a variety of oil-based, hydrophobic active ingredients used in the biopharmaceutical, cosmetics, agrochemical, health & wellness, and food/beverage areas. Mr. Schumacher will also expand on the Company's planned Fall 2022 commercialization of its revolutionary Ultra Shear Technology™ (UST™) nanoemulsification platform. Mr. Schumacher's presentation information is below:

DATE: Wednesday, May 4, 2022 (11:30am PDT ? 2:30pm EDT)
PRESENTATION: In Person and Webcast
WEBCAST: https://www.webcaster4.com/Webcast/Page/2862/45067
MEETINGS (1x1): Can be Requested on the Event Website
REGISTER: https://planetmicrocapshowcase.com

[AveragePenny]

$PBIO Keynotes, Educational Panels and 88 Companies to Present at the Planet MicroCap Showcase on May 3-5, 2022 at Bally's Hotel & Casino in Las Vegas, NV

https://www.accesswire.com/699051/keynotes-educational-panels-and-88-companies-to-present-at-the-planet-microcap-showcase-on-may-3-5-2022-at-ballys-hotel-casino-in-las-vegas-nv

LOS ANGELES, CA / ACCESSWIRE / April 27, 2022 / SNN Network presents the Planet MicroCap Showcase taking place on May 3-5, 2022, where 88 MicroCap public and private companies will be presenting at Bally's Hotel & Casino in Las Vegas, NV.

Event website: www.PlanetMicroCapShowcase.com

The Planet MicroCap Showcase begins on Tuesday, May 3, 2022 with the "MicroCap Investing Workshop" starting at 12:00pm PST and featuring well-known financial influencers, investors, fund managers, and key opinion leaders, followed by 88 MicroCap public and private company presentations on Wednesday, May 4, 2022, and 1x1 meetings on Thursday, May 5, 2022.

If you would like to attend and participate in the Planet MicroCap Showcase, please register here to attend this IN-PERSON CONFERENCE and book 1x1 meetings with presenting companies: https://planetmicrocapshowcase.com/signup

The "MicroCap Investing Workshop" and Full Agenda are available here: https://planetmicrocapshowcase.com/agenda

[AveragePenny]

$PBIO Pressure BioSciences to Discuss Recent Achievements and Upcoming Commercialization of its Enabling UST Platform at the Sequire Cannabis & Psychedelics Conference

https://www.accesswire.com/697931/pressure-biosciences-to-discuss-recent-achievements-and-upcoming-commercialization-of-its-enabling-ust-platform-at-the-sequire-cannabis-psychedelics-conference

Company Invites Investors, Analysts, and Advisors to Attend Its Virtual Presentation on Wednesday, April 20th at 10:30am EDT

SOUTH EASTON, MA / ACCESSWIRE / April 19, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" and the "Company"), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments, consumables, and specialty services to the worldwide biopharmaceuticals, cosmetics, agrochem, and food & beverage industries, today announced the Company's participation as a presenter at the April 20th Sequire Cannabis & Psychedelics Investor Conference. This virtual conference will feature over 30 top public companies in the cannabis and psychedelics space. PBI's President and CEO, Mr. Richard T. Schumacher, will expand on the Company's recent achievements in the nanoemulsification of CBD and other cannabinoids, as well as with a variety of oil-based, hydrophobic active ingredients used in the biopharmaceutical, cosmetics, agrochemical, health & wellness, and food/beverage areas. Mr. Schumacher will also expand on the Company's planned Fall 2022 commercialization of its revolutionary Ultra Shear Technology™ (UST™) nanoemulsification platform. Mr. Schumacher's presentation information is below:

DATE: Wednesday, April 20, 2022 (10:30 am EDT)
PRESENTATION: Virtual
MEETINGS (1x1): Can be Requested on the Event Website
REGISTER: Click Here to Register (free)

[fly123]

Bidders 1.85 here now

[fly123]

Volume building here , big news should be soon o would think .

[noshorthere]

Sorry about the double post.

[noshorthere]

Read it again. It wasn't higher earnings---it was higher revenue. Earnings were actually lower.... 1) increased revenue by 65% to $2, 2) increased net LOSS 25% to $20M, 3) increased convertible debt about 70% to $12.5M, 4) increased total liabilities 31% to $25M, and 5) are in default on about 40 notes.

That last pronouncement (5) means that those convertible notes will be subject to discounts up to 25% if/when converted.

This was a horrible earnings report.

[noshorthere]

Read it again. It wasn't higher earnings---it was higher revenue. Earnings were actually lower.... 1) increased revenue by 65% to $2M, 2) increased net loss 25% to $20M, 3) increased convertible debt about 70% to $12.5M, 4) increased total liabilities 31% to $25M, and 5) are in default on about 40 notes.

That last pronouncement (5) means that those convertible notes will be subject to discounts up to 25% if/when converted.

This was a horrible earnings report.

[Rick84]

Somebody explain why lower price with higher earnings???

[fly123]

Earning s report good , now looks like they will get buyout orders $30 million offered already and turned down

[AveragePenny]

$PBIO Pressure BioSciences Leveraging Strong FY2021 Operational and Financial Successes, Worldwide Customer Base, Substantial IP Estate, and Three Powerful Technology Platforms to Accelerate Strategic Company Transformation in 2022

https://www.accesswire.com/696078/pressure-biosciences-leveraging-strong-fy2021-operational-and-financial-successes-worldwide-customer-base-%20substantial-ip-estate-and-three-powerful-technology-platforms-to-accelerate-strategic-company-transformation-in-2022

Q4 and FY2021 Total Revenue Increased 91% and 64% Respectfully Over Same Periods in 2020;
PCT, BaroFold, and PBI Agrochem Groups Scored Important Gains in 2021;
UST Platform Achieved Critical 2021 Goals - Discussions Ongoing with Key Leaders in Multiple Markets

Investor Conference Call Scheduled for Tuesday April 5 at 4:30 PM ET

SOUTH EASTON, MA / ACCESSWIRE / April 5, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and innovative services to the worldwide biotherapeutics, nutraceuticals, cosmetics, agrochem, food & beverage, and other industries, today announced financial results for the fourth quarter and fiscal year ended December 31, 2021, provided a business update, and offered guidance on the Company's strategic changes and growth acceleration planned for FY 2022.

Over the past 15 years, PBI has acquired a wealth of knowledge and experience in the use of pressure to create remarkable results in a variety of commercially-attractive areas using the Company's three enabling technology platforms: Pressure Cycling Technology ("PCT"), BaroFold™, and Ultra Shear Technology™ ("UST™").

Jeffrey N. Peterson, Chairman of the PBI Board, set the stage for PBI's exciting future: "The PCT and BaroFold technologies have provided important early opportunities for commercial traction, as PBI forged scientific understanding and acceptance for its high-pressure platforms. Building on multiple peer-reviewed opinion leader scientific articles and presentations, accelerating instrument installations, and expanding paid research projects, these platforms are expected to generate important sales growth in 2022 and beyond. In addition, we believe the UST platform is opening up a new, game-changing growth trajectory with its promise for revolutionizing massive global markets from pharmaceuticals, nutraceuticals, cosmetics, agrochem, food/beverage processing, and more."

Richard T. Schumacher, President and CEO of PBI, continued the thought: "As we evaluated the prospective commercial successes for our technologies and products, UST singularly stood out. After extensive development efforts and due diligence, we came to understand that the proprietary UST platform is a disruptive technology with revenue potential that we believe can be transformative for PBI and the major markets it will serve. We have consequently focused the majority of the PBI Team's 2021 efforts on UST development and on the commercial introduction and acceleration for UST in 2022."

Mr. John Hollister joined the PBI Team as Director of Marketing and Sales in 2020. He came to PBI with broad experience in leading commercialization of major products in large companies like SmithKline (now GSK) and Amgen, as well as in the start-up world for the previous 17 years. His diverse experience in successfully developing and leading marketing programs (including initial product commercialization) with both large and modest budgets will be pivotal for PBI, as he leads our UST commercialization program. He is already driving the planning and execution of critical partnering and initial commercialization strategies in order to build rapid and robust customer adoption and to accelerate growth in 2022.

Mr. Hollister said: "The amazing PBI Team has spent years becoming experts in how to safely capture and utilize pressure to improve existing methods in research and pharmaceutical manufacturing. With the 2022 commercialization of UST, PBI will introduce to the world the full potential of what pressure can do in a variety of large and growing markets. The coming months will be a very exciting time for PBI, our customers, and for the users of their UST-processed products."

Financial Results: Q4 2021 vs. Q4 2020

Total revenue for Q4 2021 was $315,199 compared to $164,702 for the same period in 2020, a 91% increase. This increase was primarily due to our double-digit growth in products and services.
Sales of instruments increased to $115,784 in Q4 2021 compared to $0 in Q4 2020.
Consumable sales were $82,680 for Q4 2021 compared to $48,651 for the same period in 2020, a 70% increase.
Operating loss for Q4 2021 was $1,221,148 compared to $1,041,293 for the same period in 2020, primarily due to increases in general and administrative expense.
Loss per common share - basic & diluted - decreased to $(0.48) for Q4 2021 from $(1.19) for Q4 2020.
Financial Results: FY2021 vs. FY2020

Total revenue for FY 2021 was $2,002,365 compared to $1,220,591 for FY2020, a 64% increase. This increase was primarily due to our growth in products and services.
Sales of instruments increased to $1,105,268 for FY 2021 compared to $568,457 for FY 2020, an increase of 94%
Consumable sales were $274,108 for the year ended December 31, 2021 compared to $204,889 for the same period in 2020, an increase of $69,219 or 34%.
Operating loss for FY 2021 was $4,185,147 compared to $4,585,787 for FY 2020. This decrease was primarily due to increases in total revenue.
Loss per common share - basic and diluted - decreased to $(3.42) for FY2021 from $(5.32) for the 2020 fiscal year.
Operational & Technical Highlights (2021/2022)

Solid progress reported on FY 2022 key goals.
Ohio State installs/commissions BaroShear MAX UST processing equipment at renowned Food Pilot Plant.
UST processing achieves 18-month stability of CBD oil nanoemulsion.
Five UST patents awarded, including two for critical nanogap valve.
Strong demand observed for our BaroFold protein refolding platform specialty testing services.
UST successfully transforms Neem Oil into a novel highly potent nanoemulsion for effective agrochem use.
UST demo and manufacturing sites (Fall 2022) named: Boston, MA and Mountain View, CA.
PBI establishes wholly-owned PBI Agrochem subsidiary.
UST platform successfully processes one of the world's most potent antioxidants: Astaxanthin.
PBI and Ohio State University announce partnership in the formation of a food industry consortium to advance commercialization of the UST platform.
Earnings Call and Business Update

The Company will hold an Earnings Conference Call and Business Update at 4:30 PM ET on Tuesday, April 5, 2022. To attend this teleconference via telephone, Dial-in: [phone] (North America), [phone] (International). Verbal Passcode: 648452 or say Pressure BioSciences Fourth Quarter and Fiscal Year 2021 Financial Call. Replay Number [phone]; [phone] (International). Replay Passcode: 45153. Teleconference Replay Available for 30 days.

[fly123]

Open $2.40 looks like , machines get manufactured at $2.50 and company will be rolling with PO s

[fly123]

https://vm.tiktok.com/ZTdu3cYsh/ THIS ONE SET TO explode !!

[fly123]

Massive above average volume

[fly123]

Closed $2.28 what a day

[fly123]

https://www.otcmarkets.com/stock/PBIO/news/Pressure-BioSciences-Inc-to-Discuss-Fourth-Quarter-and-Fiscal-Year-2021-Financial-Results-and-Provide-Business-Update?id=350524

[fly123]

Awesome here we go up 9.9 %

[fly123]

$2.11 to $2.14

[fly123]

$2.10